The Company's aim is to seek FDA consent to fast track the Clinical Development Program to treat Basal Cell Carcinoma (BCC) of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays ...

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

The global Life Science Consulting Services Market is projected to witness robust growth, with an expected CAGR of 10% from ...

Looming threats to the pharmaceutical supply chain have brought fresh attention to onshoring. Experts say innovation is ...

Overview of Short Bowel Syndrome MarketThe Global Short Bowel Syndrome Market is valued at USD 1.76 Billion in 2024 and is projected to attain a value of USD 3.66 Billion by 2035 at a CAGR of 6.91% ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...